Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.33 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8622881 | 1.00 | FDFT1 (0.34) | FDFT1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8625461 | 0.88 | LSS (0.39) | — | |
| SCHEMBL8625468 | 0.88 | LSS (0.39) | — | |
| SCHEMBL8618340 | 0.87 | ENPP2 (0.37) | FDFT1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8618348 | 0.87 | ENPP2 (0.37) | FDFT1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8626297 | 0.86 | TRPV1 (0.38) | — | |
| SCHEMBL8626302 | 0.86 | TRPV1 (0.38) | — | |
| SCHEMBL8619754 | 0.82 | FDFT1 (0.50) | FDFT1S1PR2S1PR1S1PR3S1PR4 | |
| SCHEMBL8623984 | 0.81 | ENPP2 (0.35) | — | |
| SCHEMBL8623981 | 0.81 | ENPP2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712396-A | PHOSPHONOSULFONATE COMPOUNDS USED FOR INHIBITING CHOLESTEROL BIOSYNTHESIS AND ATHEROSCLEROSIS | MAGNIN DAVID R (US) | 1998-01-27 | — | — | US | disclosed |
| US-5567841-A | ANTICHOLESTEROL AGENT | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-22 | — | — | US | disclosed |
| US-5470845-A | Methods of using α-phosphonosulfonate squalene synthetase inhibitors including the treatment of atherosclerosis and hypercholesterolemia | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-11-28 | — | — | US | disclosed |